Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial.

Autor: Chandiwana N; Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Electronic address: nchandiwana@ezintsha.org., Kruger C; Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Johnstone H; HJ-Clinical Trial Consultancy, George, South Africa., Chughlay MF; Medicines for Malaria Venture, Geneva, Switzerland., Ju C; Shin Poong Pharm. Co. Ltd., Seoul, Republic of Korea; Graduate School of Clinical Pharmacy, CHA University, Pocheon-si, Gyeonggi-do, Republic of Korea., Kim B; Shin Poong Pharm. Co. Ltd., Seoul, Republic of Korea., Dineka Y; Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Arbe-Barnes S; Artemida Pharma, Stevenage, United Kingdom., Miller R; Artemida Pharma, Stevenage, United Kingdom., Owen A; Department of Molecular and Clinical Pharmacology, Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool, United Kingdom., Hill A; Department of Molecular and Clinical Pharmacology, Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool, United Kingdom., Windgassen D; DATAMAP, Freiburg, Germany., Abla N; Medicines for Malaria Venture, Geneva, Switzerland., Marrast AC; Medicines for Malaria Venture, Geneva, Switzerland., Duparc S; Medicines for Malaria Venture, Geneva, Switzerland., Francois Venter WD; Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Publikováno v: EBioMedicine [EBioMedicine] 2022 Dec; Vol. 86, pp. 104322. Date of Electronic Publication: 2022 Nov 01.

Rechallenge after anti-tuberculosis drug-induced liver injury in a high HIV prevalence cohort.

Autor: Moosa MS; Department of Medicine, New Somerset Hospital, Cape Town, South Africa.; Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Maartens G; Department of Medicine, Division of Clinical Pharmacology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Gunter H; Department of Medicine, Division of Clinical Pharmacology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Allie S; Department of Medicine, Division of Clinical Pharmacology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Chughlay MF; Department of Medicine, Division of Clinical Pharmacology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Setshedi M; Department of Medicine, Division of Gastroenterology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Wasserman S; Department of Medicine, Division of Infectious Diseases, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Stead DF; Department of Medicine, New Somerset Hospital, Cape Town, South Africa.; Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Cohen K; Department of Medicine, Division of Clinical Pharmacology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

Publikováno v: Southern African journal of HIV medicine [South Afr J HIV Med] 2022 Jun 14; Vol. 23 (1), pp. 1376. Date of Electronic Publication: 2022 Jun 14 (Print Publication: 2022).

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults.

Autor: Chughlay MF; Medicines for Malaria Venturegrid.452605.0, Geneva, Switzerland., Barnes KI; Division of Clinical Pharmacology, Department of Medicine, University of Cape Towngrid.7836.a, Cape Town, South Africa., El Gaaloul M; Medicines for Malaria Venturegrid.452605.0, Geneva, Switzerland., Abla N; Medicines for Malaria Venturegrid.452605.0, Geneva, Switzerland., Möhrle JJ; Medicines for Malaria Venturegrid.452605.0, Geneva, Switzerland., Griffin P; QIMR Berghofer Medical Research Institutegrid.1049.c, Brisbane, Queensland, Australia.; Q-Pharm Pty, Ltd., Herston, Queensland, Australia.; University of Queensland, Brisbane, Queensland, Australia.; Mater Health Services, South Brisbane, Queensland, Australia., van Giersbergen P; Van Giersbergen Consulting, Wuenheim, France., Reuter SE; UniSA Clinical and Health Sciences, University of South Australiagrid.1026.5, Adelaide, South Australia, Australia., Schultz HB; UniSA Clinical and Health Sciences, University of South Australiagrid.1026.5, Adelaide, South Australia, Australia., Kress A; Swiss BioQuant, Reinach, Switzerland., Tapley P; TetraQ, Brisbane, Queensland, Australia., Webster RA; QIMR Berghofer Medical Research Institutegrid.1049.c, Brisbane, Queensland, Australia., Wells T; Medicines for Malaria Venturegrid.452605.0, Geneva, Switzerland., McCarthy JS; QIMR Berghofer Medical Research Institutegrid.1049.c, Brisbane, Queensland, Australia.; University of Queensland, Brisbane, Queensland, Australia., Barber BE; QIMR Berghofer Medical Research Institutegrid.1049.c, Brisbane, Queensland, Australia., Marquart L; QIMR Berghofer Medical Research Institutegrid.1049.c, Brisbane, Queensland, Australia., Boyle MJ; QIMR Berghofer Medical Research Institutegrid.1049.c, Brisbane, Queensland, Australia., Engwerda CR; QIMR Berghofer Medical Research Institutegrid.1049.c, Brisbane, Queensland, Australia., Chalon S; Medicines for Malaria Venturegrid.452605.0, Geneva, Switzerland.

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2022 Jan 18; Vol. 66 (1), pp. e0158421. Date of Electronic Publication: 2021 Oct 25.

A Randomized Controlled Trial of Intravenous N-Acetylcysteine in the Management of Anti-tuberculosis Drug-Induced Liver Injury.

Autor: Moosa MS; Department of Medicine, University of Cape Town, Cape Town, South Africa.; Department of Medicine, New Somerset Hospital, Cape Town, South Africa., Maartens G; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa., Gunter H; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa., Allie S; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa., Chughlay MF; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa., Setshedi M; Division of Gastroenterology, Department of Medicine, University of Cape Town, Cape Town, South Africa., Wasserman S; Division of Infectious Diseases and HIV Medicine, Department of Medicine, University of Cape Town, Cape Town, South Africa., Stead DF; Department of Medicine, University of Cape Town, Cape Town, South Africa.; Department of Medicine, New Somerset Hospital, Cape Town, South Africa., Hickman N; Clinical Research Centre, University of Cape Town, Cape Town, South Africa., Stewart A; Clinical Research Centre, University of Cape Town, Cape Town, South Africa., Sonderup M; Division of Hepatology, Department of Medicine, University of Cape Town, Cape Town, South Africa., Spearman CW; Division of Hepatology, Department of Medicine, University of Cape Town, Cape Town, South Africa., Cohen K; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.

Publikováno v: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2021 Nov 02; Vol. 73 (9), pp. e3377-e3383.

Liver Enzyme Elevations in Plasmodium falciparum Volunteer Infection Studies: Findings and Recommendations.

Autor: Chughlay MF; 1Medicines for Malaria Venture, Geneva, Switzerland., Akakpo S; 1Medicines for Malaria Venture, Geneva, Switzerland., Odedra A; 2QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia., Csermak-Renner K; 3Novartis Pharma AG, Basel, Switzerland., Djeriou E; 4Sanofi, Gentilly, France., Winnips C; 3Novartis Pharma AG, Basel, Switzerland., Leboulleux D; 4Sanofi, Gentilly, France., Gaur AH; 5St. Jude Children's Research Hospital, Memphis, Tennessee., Shanks GD; 2QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia., McCarthy J; 2QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia., Chalon S; 1Medicines for Malaria Venture, Geneva, Switzerland.

Publikováno v: The American journal of tropical medicine and hygiene [Am J Trop Med Hyg] 2020 Jul; Vol. 103 (1), pp. 378-393. Date of Electronic Publication: 2020 Apr 16.